School of Medicine
Showing 4,381-4,400 of 13,083 Results
-
Rose Heald
Masters Student in Translational Research and Applied Medicine, admitted Autumn 2025
BioAs a Master’s student in Translational Research and Applied Medicine at Stanford Medicine, I’m passionate about bridging the gap between scientific discovery and real-world clinical impact. My career interests lie at the intersection of science and business, with a focus on advancing the development and implementation of novel therapeutics—particularly in the areas of genetics, rare disease, and neurodegenerative diseases.
I bring experience in clinical research, including work on the BabySeq Project, a pioneering study of genomic newborn screening (gNBS). This experience sparked my ongoing interest in how genomic technologies can be implemented to identify actionable health risks early in life. I continue to contribute to this field through my involvement with the International Consortium on Newborn Sequencing (ICoNS), a global initiative advancing gNBS research. -
Alesha Heath
Basic Life Research Scientist, Psych/Public Mental Health & Population Sciences
BioDr. Alesha Heath is a Postdoctoral Scholar at Psychiatry and Behavioral Sciences at Stanford School of Medicine and the MIRECC the VA Palo Alto. She earned her PhD from the University of Western Australia and Sorbonne University.
Dr. Heath's research has been primarily focused on the mechanisms and applications of brain stimulation therapies, in particular repetitive transcranial magnetic stimulation. Her research involves both basic and clinical components with the aim of improving the efficacy of these therapies for the treatment of disorders such as depression and Alzheimer's disease. -
Gregory M. Heestand, MD
Clinical Associate Professor, Medicine - Oncology
BioDr. Heestand is a board-certified medical oncologist with a focus on gastrointestinal cancers, primarily hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancer. He serves as the medical oncology champion of the Stanford Hepatobiliary Tumor Board, as well as the principal investigator of multiple clinical trials. He collaborates with campus laboratories to help develop new biomarker and treatment technologies. He is the former director of the Stanford Oncology Fellowship Program.
Dr. Heestand and his team take great pride in helping patients and their families face gastrointestinal cancer.
Outside of the clinic, Dr. Heestand enjoys playing the piano, teaching his kids about music, cooking for friends and family, and surfing the internet for interesting things to read. -
Katherine (Heflin) Hefcart
Affiliate, Department Funds
Resident in Psychiatry and Behavioral SciencesBioAdult Psychiatry Resident, focusing on Community/Public Psychiatry, LGBTQ+ competent care, integrative mental health, and reproductive psychiatry. Attended Stanford undergraduate ('11), Harvard T.H. Chan School of Public Health ('15), Dartmouth Geisel Medical School ('23).
-
Nuriya Ruth Hefron
Training & Technical Assistance Manager, Psych/Public Mental Health & Population Sciences
Current Role at StanfordProgram Manager INSPIRE 360
Expansion of Early Psychosis Care Program -
John P. Hegarty II
Clinical Assistant Professor, Psychiatry and Behavioral Sciences
BioI am a neuroscientist and Principal Investigator of the Stanford Clinical Neuroscience (CNS) Lab in the Department of Psychiatry and Behavioral Sciences as well as Director of Neuroimaging for the Autism and Developmental Disorders Research Program at Stanford. My innovative research studies clinical aspects of cognitive and behavioral neuroscience, with a special focus on examining the neural circuitry associated with important brain-behavior relationships that may underlie different psychological and psychiatric domains in autistic children, adolescents, and adults. The ultimate goal of this research is to improve our understanding of the development of different cognitive and behavioral skills in order to develop mechanistically driven interventions that will improve precision medicine for mental health. Biologically based diagnosis and treatment are extremely limited for most psychological and psychiatric conditions but also critically needed to increase early identification and improve treatment outcomes, especially for neurodevelopmental disorders in which early intervention is the most beneficial. My early career research has primarily focused on clinical neuroscience using neuroimaging (e.g., MRI & EEG) to examine the effects of different drugs and behavioral interventions on the brain, especially for developing biomarkers for improving treatment planning and monitoring biological changes in response to single dose and clinical trials.
My primary contributions to science thus far fall within these major categories: 1) identifying the neural correlates of individual differences in cognition and behavior, 2) developing new interventions and investigating the neurobiological substrates of response to treatment, 3) examining different factors that contribute to brain development, 4) summarizing and increasing accessibility to autism-related research, and 5) methods development for neuroimaging studies. My earliest research investigated the neurobiology of alexithymia, dyslexia, and stress using structural and functional magnetic resonance imaging to test theories of the mechanisms that contribute to differences in cognition and behavior. My subsequent dissertation research, in which I began to focus on neurodevelopmental disorders, examined the neural correlates of response to beta-blockers in autistic adults and also assessed the contribution of cerebellar circuits to the autism phenotype. During my postdoctoral training, I have developed further skills for working with children in multiple clinical research settings, especially for using advanced neuroimaging approaches to examine important brain-behavior relationships. This includes a recent K99/R00 from the National Institute of Child Health and Human Development (NCT04278898 & NCT05664789) that will assess the neurobiology of restricted and repetitive behaviors in autistic children and examine the efficacy and target engagement of a novel nutritional supplement and investigational drug, N-acetylcysteine (NAC), in the brain. You can find more information about our NAC studies at https://redcap.link/NACandAutism. -
Shireen N. Heidari
Clinical Associate Professor, Medicine - Primary Care and Population Health
BioShireen Heidari, MD is a palliative care and family medicine physician. She works as part of the inpatient palliative care consult team providing symptom management and support for patients and families facing any stage of a serious illness. Dr. Heidari is the program director for the Stanford University Hospice and Palliative Fellowship. She previously served as the clinical lead for the Stanford site of the PERIOP-PC Study, collaborating with the surgical department to evaluate the impact of early palliative care support for patients and family members preparing for major upper gastrointestinal cancer surgery.
Dr. Heidari is also a writer whose pieces about the importance of human connection, tough conversations, and stigma around healthcare workers seeking help for their mental health have been published in The New England Journal of Medicine, The Lancet Respiratory Medicine, CHEST, The Journal of Pain and Symptom Management, and the Intima. She hopes that by sharing her own story, she can continue being part of these conversations as we advocate for culture change in medicine and more sustainable practice.
Before moving to northern California, Dr. Heidari attended medical school at Boston University, completed her residency at UC San Diego where she served as chief resident, followed by palliative fellowship at UCLA. Outside of her clinical and mentorship work, she is likely writing creatively or outside with her husband chasing their dogs. She is currently writing her first fiction novel. -
Paul Heidenreich, MD
Professor of Medicine (Cardiovascular)
On Partial Leave from 05/01/2026 To 06/30/2026Current Research and Scholarly InterestsMy research interests include
1) The cost-effectiveness of new cardiovascular technologies.
Example: tests to screen asymptomatic patients for left ventricular systolic dysfunction.
2) Interventions to improve the quality of care of patients with heart disease. Examples: include clinical reminders and home monitoring.
3) Outcomes research using existing clinical and administrative datasets.
4) Use of echocardiography to predict prognosis (e.g. diastolic dysfunction).
